home / stock / fulc / fulc quote
Last: | $ |
---|---|
Change Percent: | -3.21% |
Open: | $16.30 |
Close: | $15.68 |
High: | $16.30 |
Low: | $15.40 |
Volume: | 41,328 |
Last Trade Date Time: | 02/12/2020 04:43:03 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $16.30 | $15.68 | $16.30 | $15.40 | 41,328 | 02-12-2020 |
$ | $16.29 | $16.20 | $17.5631 | $16.0074 | 58,493 | 02-11-2020 |
$ | $17.89 | $16.20 | $18.05 | $16.04 | 47,971 | 02-10-2020 |
$ | $16.71 | $17.97 | $18.07 | $16.71 | 50,506 | 02-07-2020 |
$ | $16.36 | $16.72 | $17.395 | $16.1773 | 58,747 | 02-06-2020 |
$ | $17.09 | $16.86 | $17.46 | $16.57 | 55,543 | 02-05-2020 |
$ | $17.29 | $17.00 | $17.565 | $16.00 | 113,076 | 02-04-2020 |
$ | $17.54 | $17.12 | $17.85 | $17.05 | 69,691 | 02-03-2020 |
$ | $17.95 | $17.24 | $18.41 | $17.10 | 61,220 | 01-31-2020 |
$ | $18.12 | $17.89 | $18.46 | $17.20 | 64,923 | 01-30-2020 |
$ | $17.58 | $18.23 | $19.10 | $17.37 | 96,862 | 01-29-2020 |
$ | $18.45 | $17.40 | $18.70 | $17.07 | 95,687 | 01-28-2020 |
$ | $17.09 | $18.13 | $19.60 | $17.00 | 108,761 | 01-27-2020 |
$ | $17.17 | $17.00 | $19.50 | $16.87 | 105,610 | 01-24-2020 |
$ | $17.73 | $16.87 | $18.28 | $16.78 | 65,997 | 01-23-2020 |
$ | $19.30 | $17.53 | $19.7378 | $17.16 | 85,350 | 01-22-2020 |
$ | $20.00 | $18.98 | $20.85 | $18.84 | 59,879 | 01-21-2020 |
$ | $18.89 | $19.89 | $21.00 | $18.495 | 150,556 | 01-20-2020 |
$ | $18.89 | $19.89 | $21.00 | $18.495 | 150,276 | 01-17-2020 |
$ | $18.3521 | $18.88 | $19.49 | $18.00 | 45,570 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.9% on the day to $7.74. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with gen...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmac...
CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today ...